Drugs / Chlamydia mRNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06891417 | Mar 2025 → Jan 2028 expected | chlamydia trachomatis infectious disease | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlamydia mRNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06891417 ↗ |
| Modality | Messenger RNA (mRNA) | “Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate” NCT06891417 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT06891417 ↗ |